S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
NASDAQ:SMMT

Summit Therapeutics Stock Forecast, Price & News

$5.16
-0.27 (-4.97%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.13
$5.43
50-Day Range
$4.83
$6.48
52-Week Range
$4.26
$12.30
Volume
53,112 shs
Average Volume
203,113 shs
Market Capitalization
$504.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.95
30 days | 90 days | 365 days | Advanced Chart
Receive SMMT News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Summit Therapeutics logo

About Summit Therapeutics

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Headlines

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up to $5.26
November 26, 2021 |  americanbankingnews.com
Summit Therapeutics Inc. (NASDAQ:SMMT) Short Interest Update
November 20, 2021 |  americanbankingnews.com
Summit Therapeutics (NASDAQ:SMMT) Shares Up 6.5%
November 17, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SMMT
Employees
80
Year Founded
N/A

Sales & Book Value

Annual Sales
$20.17 million
Book Value
$0.96 per share

Profitability

Net Income
$-52.70 million
Net Margins
-350.72%
Pretax Margin
-351.29%

Debt

Price-To-Earnings

Miscellaneous

Free Float
24,550,000
Market Cap
$504.20 million
Optionable
Optionable

Company Calendar

Last Earnings
11/15/2021
Today
11/26/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/16/2022

MarketRank

Overall MarketRank

1.13 out of 5 stars

Medical Sector

1213th out of 1,392 stocks

Pharmaceutical Preparations Industry

576th out of 670 stocks

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Summit Therapeutics (NASDAQ:SMMT) Frequently Asked Questions

How has Summit Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Summit Therapeutics' stock was trading at $1.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SMMT stock has increased by 173.0% and is now trading at $5.16.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Summit Therapeutics?

Summit Therapeutics saw a decline in short interest during the month of October. As of October 29th, there was short interest totaling 420,300 shares, a decline of 22.3% from the October 14th total of 540,600 shares. Based on an average daily volume of 154,900 shares, the days-to-cover ratio is presently 2.7 days. Approximately 1.7% of the company's stock are short sold.
View Summit Therapeutics' Short Interest
.

When is Summit Therapeutics' next earnings date?

Summit Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 16th 2022.
View our earnings forecast for Summit Therapeutics
.

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics Inc. (NASDAQ:SMMT) released its earnings results on Monday, November, 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.29) by $0.09. Summit Therapeutics had a negative trailing twelve-month return on equity of 96.34% and a negative net margin of 350.72%.
View Summit Therapeutics' earnings history
.

Who are Summit Therapeutics' key executives?

Summit Therapeutics' management team includes the following people:
  • Mr. Robert W. Duggan, Exec. Chairman & CEO (Age 77) (LinkedIn Profile)
  • Mr. Michael Paul Donaldson, Chief Financial Officer (Age 44, Pay $296.2k)
  • Dr. Mahkam Zanganeh M.B.A., D.D.S., MBA, COO & Director (Age 51, Pay $459.38k)
  • Prof. Dame Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 71)
  • Dr. David Jonathan Powell, Chief Scientific Officer (Age 51)
  • Ms. Michelle Avery, Director of Investor Relations
  • Mr. Dave Gancarz, Head of Investor Relations & Corp. Strategy
  • Ms. Christine Armstrong, VP of Marketing?
  • Mr. Campbell Hair, Head of HR?
  • Dr. Jonathon Tinsley, Chief Scientific Officer of DMD (Age 62)

What other stocks do shareholders of Summit Therapeutics own?

When did Summit Therapeutics IPO?

(SMMT) raised $40 million in an initial public offering on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.

What is Summit Therapeutics' stock symbol?

Summit Therapeutics trades on the NASDAQ under the ticker symbol "SMMT."

Who are Summit Therapeutics' major shareholders?

Summit Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Polar Capital Holdings Plc (6.57%), BlackRock Inc. (1.23%), Morgan Stanley (0.29%), Geode Capital Management LLC (0.26%), Russell Investments Group Ltd. (0.09%) and Bank of New York Mellon Corp (0.05%). Company insiders that own Summit Therapeutics stock include David Jonathan Powell, Maky Zanganeh and Robert W Duggan.
View institutional ownership trends for Summit Therapeutics
.

Which institutional investors are selling Summit Therapeutics stock?

SMMT stock was sold by a variety of institutional investors in the last quarter, including Polar Capital Holdings Plc, California State Teachers Retirement System, Arrowstreet Capital Limited Partnership, Citadel Advisors LLC, and New York State Common Retirement Fund.
View insider buying and selling activity for Summit Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Summit Therapeutics stock?

SMMT stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Russell Investments Group Ltd., Morgan Stanley, Geode Capital Management LLC, SG Americas Securities LLC, Inscription Capital LLC, Bank of New York Mellon Corp, and Advisor Group Holdings Inc.. Company insiders that have bought Summit Therapeutics stock in the last two years include Maky Zanganeh, and Robert W Duggan.
View insider buying and selling activity for Summit Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Summit Therapeutics?

Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Summit Therapeutics' stock price today?

One share of SMMT stock can currently be purchased for approximately $5.16.

How much money does Summit Therapeutics make?

Summit Therapeutics has a market capitalization of $504.20 million and generates $20.17 million in revenue each year. The company earns $-52.70 million in net income (profit) each year or ($0.92) on an earnings per share basis.

How many employees does Summit Therapeutics have?

Summit Therapeutics employs 80 workers across the globe.

What is Summit Therapeutics' official website?

The official website for Summit Therapeutics is www.summitplc.com.

Where are Summit Therapeutics' headquarters?

Summit Therapeutics is headquartered at 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB.

How can I contact Summit Therapeutics?

Summit Therapeutics' mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via phone at 617-514-7149, via email at [email protected], or via fax at 44-12-3544-3999.


This page was last updated on 11/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.